Peripheral Neuropathy, Aseptic Meningitis, Encephalitis

OVERVIEW

GUIDELINES

Neurologic–Peripheral Neuropathy, Aseptic Meningitis, Encephalitis

Neurologic–Peripheral Neuropathy (Motor or sensory)

Reference:

  1. NCCN (National Comprehensive Cancer Network) V.1.2023. Accessed at: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Last accessed: 1-5-2023
  2. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Accessed at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Last accessed: 15-1-2023.
  3. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of clinical oncology. 2023;39(36):4073-126.
  4. Haanen , Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(12):1217-38.
  5. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer. 2021;9(6)